Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

CytomX Therapeutics (CTMX) FCF Margin (2016 - 2025)

Historic FCF Margin for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to 258.61%.

  • CytomX Therapeutics' FCF Margin fell 1965500.0% to 258.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 63.67%, marking a year-over-year increase of 64500.0%. This contributed to the annual value of 62.66% for FY2024, which is 64700.0% down from last year.
  • According to the latest figures from Q3 2025, CytomX Therapeutics' FCF Margin is 258.61%, which was down 1965500.0% from 84.57% recorded in Q2 2025.
  • Over the past 5 years, CytomX Therapeutics' FCF Margin peaked at 39.58% during Q1 2023, and registered a low of 465.14% during Q1 2022.
  • Moreover, its 5-year median value for FCF Margin was 84.57% (2025), whereas its average is 169.22%.
  • In the last 5 years, CytomX Therapeutics' FCF Margin crashed by -17109300bps in 2021 and then skyrocketed by 5047200bps in 2023.
  • Over the past 5 years, CytomX Therapeutics' FCF Margin (Quarter) stood at 282.4% in 2021, then skyrocketed by 97bps to 7.83% in 2022, then tumbled by -967bps to 83.55% in 2023, then skyrocketed by 37bps to 52.47% in 2024, then tumbled by -393bps to 258.61% in 2025.
  • Its last three reported values are 258.61% in Q3 2025, 84.57% for Q2 2025, and 41.56% during Q1 2025.